ACADIA Pharmaceuticals Inc.
$22.09
▼
-0.54%
2026-04-21 05:02:00
www.acadia.com
NMS: ACAD
Explore ACADIA Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.77 B
Current Price
$22.09
52W High / Low
$28.35 / $14.08
Stock P/E
9.63
Book Value
$7.21
Dividend Yield
—
ROCE
8.14%
ROE
39.89%
Face Value
—
EPS
$2.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
796
Beta
0.83
Debt / Equity
4.25
Current Ratio
3.83
Quick Ratio
3.71
Forward P/E
23.63
Price / Sales
3.46
Enterprise Value
$2.94 B
EV / EBITDA
25.21
EV / Revenue
2.74
Rating
Buy
Target Price
$31.8
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Azitra, Inc. | $0.21 | — | $3.48 M | — | -277.12% | -2.31% | $2.66 / $0.1 | $0.35 |
| 2. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 3. | Mustang Bio, Inc. | $0.74 | — | $5.61 M | — | -25.13% | -67.93% | $7 / $0.53 | $1.31 |
| 4. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 5. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 6. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
| 7. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 283.99 M | 278.63 M | 264.57 M | 244.32 M | 259.6 M |
| Operating Profit | 17.39 M | 35.76 M | 32.37 M | 19.29 M | 6.99 M |
| Net Profit | 273.57 M | 71.78 M | 26.67 M | 18.99 M | 143.74 M |
| EPS in Rs | 1.6 | 0.42 | 0.16 | 0.11 | 0.84 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.07 B | 957.8 M | 726.44 M | 517.24 M |
| Operating Profit | 104.81 M | 84.28 M | -73.38 M | -223.6 M |
| Net Profit | 391 M | 226.45 M | -61.29 M | -215.97 M |
| EPS in Rs | 2.29 | 1.33 | -0.36 | -1.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.56 B | 1.19 B | 748.96 M | 587.81 M |
| Total Liabilities | 336.81 M | 454.96 M | 317.2 M | 187.4 M |
| Equity | 1.23 B | 732.79 M | 431.75 M | 400.41 M |
| Current Assets | 1.06 B | 938.32 M | 616.12 M | 507.94 M |
| Current Liabilities | 277.11 M | 394.87 M | 254.25 M | 125.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 109.84 M | 157.72 M | 16.7 M | -114.03 M |
| Investing CF | -302.56 M | -30.54 M | 32 M | 73.24 M |
| Financing CF | 49.88 M | 6.84 M | 25.13 M | 8.2 M |
| Free CF | 105.15 M | 157.2 M | 16.65 M | -114.03 M |
| Capex | -4.69 M | -0.52 M | -0.05 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 31.85% | 40.45% | — | — |
| Earnings Growth % | 469.5% | 71.62% | — | — |
| Profit Margin % | 23.64% | -8.44% | -41.76% | — |
| Operating Margin % | 8.8% | -10.1% | -43.23% | — |
| Gross Margin % | 91.46% | 94.27% | 98.03% | — |
| EBITDA Margin % | 10.46% | -9.34% | -42.84% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.